Author name: Leonardo Arias

The ruling keeps some protections for gender-affirming care in place, but also upholds several other controversial policies paring back the ACA finalized in a rule last year.

The agency published a discussion paper this week as it considers the “unique risks” and potential promise of generative AI for patient care.

Ochsner Health in Louisiana is the first to go live with Epic’s new outpatient office visit tool, which leans on Epic’s artificial intelligence capabilities to pull insights from patient records.

The health system closed its $835 million acquisition of the virtual therapy provider on Monday. Healthcare Dive caught up with Marc Miller to discuss the rationale behind the deal.

Melanoma was slower to recur in patients receiving Merck and Moderna’s mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.

Looking for a biopharma job in New Jersey? Job postings in the area have increased year over year, according to BioSpace data. Here are 11 companies with open roles.

As Abbott prepares to launch its first dual-analyte sensor, endocrinologists talked to MedTech Dive about considerations for continuous ketone monitoring.

If Heidi Overton clears the Senate nomination process, analysts say she will have a tough job ahead to “restore predictability” to an agency battered by layoffs and controversial policies.

Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.

Amylyx shares good news for its investigational GLP-1 blocker; Definium announces positive data for its LSD-based therapy in anxiety; Summit/Akeso’s ivonescimab shows degrading survival benefits; patients treated with Neurocrine’s Prader-Willi drug experience serious adverse events; and Eli Lilly cracks down on the black market for next-gen obesity asset retatrutide.